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Exposure to toxic metals poses a serious human health hazard based on ubiquitous
environmental presence, the extent of exposure, and the toxicity and disease states
associated with exposure. This global health issue warrants accurate and reliable models
derived from the risk assessment process to predict disease risk in populations. There
has been considerable interest recently in the impact of environmental toxicants such as
toxic metals on the epigenome. Epigenetic modifications are alterations to an individual’s
genome without a change in the DNA sequence, and include, but are not limited to, three
commonly studied alterations: DNA methylation, histone modification, and non-coding
RNA expression. Given the role of epigenetic alterations in regulating gene and thus
protein expression, there is the potential for the integration of toxic metal-induced
epigenetic alterations as informative factors in the risk assessment process. In the present
review, epigenetic alterations induced by five high priority toxic metals/metalloids are
prioritized for analysis and their possible inclusion into the risk assessment process is
discussed.
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INTRODUCTION
RISK ASSESSMENT
The US Environmental Protection Agency (EPA) conducts
human health risk assessments for toxic chemicals using a four
tier process as part of the Integrated Risk Information System
(IRIS) Program (EPA, 2014a). This four step process includes
hazard identification, dose-response assessment, exposure assess-
ment, and risk characterization (EPA, 2014b). At its core, the
aim of the risk assessment process is to determine whether expo-
sure to a particular agent has the potential to induce deleterious
health outcomes, and to quantify the risk associated with var-
ious exposures. In order to conduct such an assessment, the
chemical/agent’s mode andmechanism of action are ideally deter-
mined, as well as the toxicokinetics (TK) and toxicodynamics
(TD) associated with the chemical agent (EPA, 2007).
The human health risk assessment process begins by first
defining the individuals or populations at risk, the sources and
routes of exposure, associated adverse health outcomes, and any
cofounding variables which may affect analyses of exposure or
disease state (EPA, 1992). Once these factors have been defined,
the process of hazard identification can be initiated. Hazard
identification aims to determine whether a particular agent may
increase the incidence of specific adverse health outcomes, and
whether such outcomes are likely in humans (EPA, 2012a). Here
any relevant data from human clinical or epidemiological stud-
ies are used to determine if there are associations between an
agent and adverse health outcomes (EPA, 2009). Utilizing both
human in vivo and in vitro models, the mode of action for a par-
ticular agent is investigated (reviewed in Clewell, 2005; Crump,
2011), as well as the toxicokinetic and toxicodynamic profiles
(Heinrich-Hirsch et al., 2001). However, if little or no data exists
for a particular agent or environmental toxicant in humans, ani-
mal studies will be reviewed and assessed but must statistically
account for uncertainties arising from utilizing animal models in
place of human data (Dellarco and Baetcke, 2005).
The next step of the human health risk assessment process
is the dose-response assessment. The dose-response assessment
seeks to determine a relationship between exposure to an agent
and the severity and incidence of adverse health effects (EPA,
2014a,b). First, data are analyzed to identify ranges of exposure
or dose and correlated with changes in adverse health outcomes,
as well as any mechanisms of action associated with the adverse
health outcomes. Again, where human data are scarce, data from
rodent or primate models will be utilized. It is often rare that
ample data are available for a particular agent to cover the range
of exposures being studied. In these cases, extrapolation is used
to estimate health outcomes for particular exposures. It is at this
stage that modeling of the dose-response of a particular agent has
included uncertainty factors (UFs) (Stedeford et al., 2007). UFs
have been utilized to compensate for limited data, including data
obtained from animal models and variability between human
populations. These UFs may be multiplied together, and used
alongside measurements of effect such as the benchmark dose
(BMD) and benchmark dose lower confidence limit (BMDL),
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no observed adverse effect level (NOAEL), or lowest observed
adverse effect level (LOAEL) to determine the reference dose
(RfD) (EPA, 1993), or reference concentration (RfC). The RfD
and RfC are calculated as an estimated level of daily oral and
inhalation exposure that present no increased lifetime risk of
negative health effects from a particular agent. Lastly, a dose-
response relationship is determined by utilizing the analyzed data
to determine linearity between exposure to the agent and disease
or mechanism of action; furthermore, any correlations between
dose or exposure and the mode of action can be utilized to
determine if there are biological threshold values (EPA, 2011,
2012b).
Following the dose-response assessment, an exposure assess-
ment is conducted to quantify an individual or population’s
exposure (EPA, 2011). The intent of the exposure assessment
is to estimate or measure the duration, frequency, and extent
of human exposure to the agent under conditions to which the
individual or population is likely to be exposed (EPA, 2014b).
While hazard identification and dose-response assessments pro-
vide associations between an agent and adverse health outcomes,
quantification of exposure is necessary to formulate and classify
the overall risk of the agent. For example, an extremely car-
cinogenic agent may not pose a health risk if the opportunity
for exposure to the agent is insignificant or non-existent (EPA,
2005a). These data are collected to quantify the types of expo-
sure, length of exposure, frequency, and intake route, to include
absorption, distribution, and excretion of the agent (EPA, 1992).
This information is then utilized both in the risk characterization
step, as well as a means of determining vulnerable populations,
such as children, whom may experience higher exposure or may
be highly susceptible to the agent (EPA, 2005b).
The final step in the human health risk assessment process is
risk characterization. The risk characterization is based upon the
type and degree of risk, and consists of an integrative analysis of
the summarized findings of each of the previous assessments with
their associated uncertainties (EPA, 2000). The compiled analyses
are used to make recommendations concerning the risk an agent
may pose to the population, and such recommendations may be
utilized to drive policy making and form regulations (Schmidt,
2004).
EPIGENETIC DATA IN THE RISK ASSESSMENT PROCESS
Environmental contaminants have the potential to mediate dis-
ease states through perturbations in key signaling pathways via
differential gene expression. Such perturbation can ultimately
result in altered protein expression and activity. In the last
two decades, research has shown that epigenetic alterations, a
term describing the processes that govern heritable alterations
in genomic expression that are not dependent upon changes in
the DNA sequence (Cortessis et al., 2012), play a major role
in the transcriptional processes that regulate gene expression.
Epigenetic alterations regulate homeostatic and inducible gene
expression and include but are not limited to DNA methylation,
the post-translational modifications of histones, and small non-
coding RNAs (Weake and Workman, 2010). The field of toxico-
epigenomics, which is the study of the relationship between
epigenetic alterations and adverse cellular outcomes in response
to toxic agents, is now at the forefront of the field of environ-
mental health science. It is possible that the epigenetic alterations
associated with exposure to environmental toxicants may be
key factor in the etiology of environmentally-associated diseases
(Dolinoy and Jirtle, 2008; Baccarelli and Bollati, 2009; Haluskova,
2010; Hou et al., 2012). However, the role/potential utility of
epigenetic data in the risk assessment process has yet to be
defined.
The interest in utilizing toxico-epigenomic data builds upon
the history of the desire for the incorporation of toxico-genomic
data in the risk assessment process. Toxico-genomics, the study of
the relationship between the products of the genome, mRNA and
protein, and the cellular response to toxic insult, garnered much
interest with the advent of high throughput technologies devel-
oped in the late, 1990s such as the gene expression microarray.
Genome-wide profiling of transcriptional responses as a conse-
quence of exposure to toxicants has allowed for the harnessing of
the predictive value of mRNA transcripts in relation to the patho-
genesis and progression of environmental contaminant-induced
disease (Aardema and MacGregor, 2002). Gene expression pro-
filing has been considered a potential tool in the risk assessment
process (Pennie et al., 2004; Bourdon et al., 2013; Euling et al.,
2013), based on the principles that toxicity induces changes in
gene expression patterns, adverse outcomes in response to toxicity
are a result of differential gene expression, and gene expres-
sion in response to toxicity is sensitive and expression patterns
may serve as biomarkers (Aardema and MacGregor, 2002). The
identification of transcriptional events that mediate pathogenic
processes allows those events to serve as biomarkers in the risk
assessment process. Several investigations have utilized gene pro-
filing to predict biological outcomes in response to contaminant
exposure (Wang et al., 2005). Transcript profiles have also been
correlated with associated biological pathways, such as inflam-
mation and oxidative stress (Scandalios, 2005; Beaulieu et al.,
2014).
If adverse health outcomes can be predicted based upon gene
expression profiles, then factors controlling gene expression may
also be used to predict these same outcomes. Epigenetic data may
therefore be used to inform the risk assessment process given the
epigenetic regulation of gene expression in response to toxicants.
There are several benefits of using epigenetic data as deter-
minants in the risk assessment process. For example, epigenetic
alterations can be used as biomarkers of effect upon exposure to
environmental toxicants. These epigenetic biomarkers may also
be employed as predictors of disease when such epigenetic marks
are associated with differential gene expression. There is also
the potential that such alterations may be heritable and there-
fore stable in the context of detection. They may also predict
or demonstrate possible inherited gene expression changes in
response to maternal toxicant exposure (as reviewed in Ho et al.,
2012). As a result, there is the potential that epigenomic data may
ultimately inform TD, TK, the inter- and intra-species differences
in TD and TK, mechanisms of action, mode of action, and con-
tribute to the exposure and dose-response assessment. Ultimately,
such toxico-epigenomic data may be useful in the risk characteri-
zation process and add additional accuracy to the risk assessment
process.
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In order to incorporate epigenetic data in the risk assess-
ment process, the following parameters must be addressed: are
toxicant-induced epigenetic alterations dose responsive, are the
changes toxicant specific, are the modifications genome-wide
or gene specific, and are the modifications accurate predic-
tors of biological endpoints? In the context of epigenetic data
that could inform human health risk assessment, an overview
of epigenetic alterations in the context of five priority toxic
metals and their relationship to gene expression and disease is
presented.
EPIGENETICS AND GENE EXPRESSION CHANGES
Epigenetic alterations regulate key events in cellular homeosta-
sis, including transcriptional and translational regulation of gene
expression. The most well studied epigenetic alterations are
DNA methylation, the covalent, post-translational modification
of histones, and non-coding small RNAs (miRNA). Epigenetic
alterations can be induced by environmental stimuli, and much
attention has been given to the role of the epigenome in human
disease (Skinner, 2011); a role that arises primarily from the con-
trol the epigenome exerts over the transcriptome and proteome.
The transcriptome, which is the total transcribed RNA of
a cell at a given point in time, is regulated primarily through
transcription and mRNA stability and degradation. DNA methy-
lation, histone modifications, and miRNA all regulate the tran-
scriptome through transcriptional processes. The proteome, the
total protein of the cell, is the functional mediator between
the genome and the cell and is regulated primarily through
post-transcriptional regulation of mRNA transcripts (Figure 1).
Epigenetic regulation of the proteome occurs primarily through
the action of miRNAs on mRNA transcript stability and
translation.
The epigenetic event of DNA methylation
DNA methylation is the most well-studied epigenetic alteration.
The transfer of a methyl group to cytosine forms 5-methyl cyto-
sine (5-MeC) which occurs preferentially, though not exclusively,
on cytosines in CpG dinucleotides. The DNA methyltransferase
(DNMT) family mediates the methylation of cytosines through
the transfer of a single methyl group from S-adenosine methion-
ine (SAM) to cytosine. At present, there has been no identification
of a single enzyme which exclusively demethylates DNA (Brocato
and Costa, 2013).
It is believed that CpG methylation silences genes by
preventing access of transcription factors to their respective bind-
ing sites either directly by methylation of transcription factor
binding sequences, or through the recruitment of methyl-CpG-
binding domain (MBD) proteins. MBD proteins may directly
block transcription factor binding or recruit chromatin modifiers
that alter the chromatin structure into a more transcriptionally
repressive environment (Newell-Price et al., 2000). In regulating
gene transcription, DNA methylation has been implicated in dis-
ease. DNA methylation is associated with cancer and in some
cases has proven to be a viable biomarker for disease. For exam-
ple, DNA hypermethylation of the glutathione S-transferase pi 1
(GSTP1) gene was correlated with prostate cancer (Esteller et al.,
1998), thus serving as a diagnostic tool, while hypermethylation
FIGURE 1 | The role of the epigenome in toxic metal-induced disease
pathways. Epigenetic alterations classified broadly as effects to the
“epigenome” have the potential to regulate mRNAs/transcripts (i.e., the
transcriptome) and ultimately impact protein expression (i.e., the proteome)
within cells. Exposure to toxic metals can impact various components of
the epigenetic machinery. These toxic metal-mediated epigenetic
alterations may directly impact gene transcription and subsequently
regulate protein translation, leading to aberrant expression of key mediators
of disease processes.
of O 6-methylguanine-DNA methyltransferase (MGMT) aids in
decisions for therapeutic strategies for glioma (Esteller et al.,
2000). In addition to cancer, DNA methylation is associated with
Alzheimer’s disease, diabetes, atherosclerosis, Friedrich’s ataxia,
immunodeficiency, rheumatoid arthritis, multiple sclerosis, and
systemic lupus erythematosus (Heyn and Esteller, 2012).
The epigenetic event of histone modification
To accommodate the size of the genome, DNA is packaged
into chromatin. Chromatin may be partitioned into condensed
regions known as heterochromatin, or more “relaxed,” accessi-
ble regions called euchromatin (Felsenfeld and Groudine, 2003).
Any cellular function involving DNA is inherently affected by the
chromatin structure; gene regulation, DNA replication, repair,
condensation, and segregation are all highly regulated by chro-
matin remodeling (Weake and Workman, 2010), which is the
modulation of the chromatin structure. In gene transcription for
example, large transcriptional components must have access to
binding elements within the gene promoter, and so chromatin
remodeling is necessary to procure a “relaxed” state to allow
access. The central component of chromatin is the nucleosome,
consisting of 147 bp of DNA wrapped ∼1.7 superhelical turns
around an octamer of the core histone proteins H2A, H2B, H3,
and H4 (Kinner et al., 2008). Histones share the presence of an
N-terminal tail that can be post-translationally modified (Kinner
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et al., 2008). It is in part through the post-translational, covalent
modification of histones that chromatin remodeling is mediated.
There are several distinct classes of histone modifications;
lysine acetylation, methylation, ubiquitylation, and sumoylation;
argininemethylation and deamination; proline isomerization and
glutamate poly-ADP ribosylation; and lastly, serine and threonine
phosphorylation (Wang et al., 2007). Histone modifications are
mediated by histone acetyltransferases (HAT), histone deacety-
lases (HDAC), serine and threonine kinases, phosphatases, and
histone methyltransferases and demethylases (Berger, 2007). In
addition to the complexity enabled by multiple histone modifi-
cations, single histone modifications can offer even more com-
plexity by the mono, di, or even tri-methylation of a single lysine
residue or the symmetrical or asymmetrical di-methylation of
arginines (Berger, 2007).
Histone modifications regulate transcription through a vari-
ety ofmeans, from directly disrupting DNA-nucleosome contacts,
to recruiting and binding non-histone proteins and additional
histone modifiers. Histone modifications may disrupt contact
between DNA and histones through histone lysine acetylation
and methylation, resulting in “relaxed” and condensed chro-
matin states, respectively, which are generally correlated with
transcriptional activation and repression (Reinke and Horz, 2003;
Shogren-Knaak et al., 2006; Grewal and Jia, 2007). However,
the disruption of DNA-histone contact is not mediated solely
by the direct effect of a single (or multiple) histone modifica-
tion, but in conjunction with the recruitment of non-histone
proteins to the modified histone residue. Histone modifications
recruit non-histone proteins through specific binding domains.
Through these binding domains, non-histone effectors bind
histone modifications, resulting in further chromatin remodel-
ing. Several aspects of the transcriptional process are governed
by histone modifications, including enhancer element activa-
tion, accessibility of the transcription start site, RNA polymerase
recruitment, transcriptional initiation, and others beyond the
scope of this review (Weake and Workman, 2010; Gardner et al.,
2011).
Altered histone modifications have the potential to impact
differential gene and subsequent protein expression. Differential
histone modifications have therefore been implicated in several
diseases, including cancers, and non-cancer endpoints such as
Parkinson’s and Huntington’s disease (Heyn and Esteller, 2012).
Interestingly, other diseases associated with differential histone
modification such as Alzheimer’s disease, diabetes, atherosclero-
sis, Friedrich’s ataxia, and systemic lupus erythematosus, are also
associated with aberrant DNA methylation (Heyn and Esteller,
2012).
The epigenetic event of miRNA signaling
miRNAs are small, non-coding RNAs ∼21–23 nucleotides
in length that post-transcriptionally regulate gene expression
through complementary binding of 3′ or 5′ untranslated regions
(3′ or 5′ UTR) of mRNA. miRNA target the transcripts for degra-
dation or to prevent translation, resulting in decreased target
protein expression, though it has been reported that miRNAs
may activate translation (Vasudevan et al., 2007; Breving and
Esquela-Kerscher, 2010). miRNAsmay also regulate transcription
by directly binding to gene promoter sequences and inducing
chromatin remodeling (Zardo et al., 2012).
miRNA sequences are located in specifically associated pro-
moters, or even embedded in host genes (Breving and Esquela-
Kerscher, 2010). After transcription miRNAs are processed in the
nucleus to form hair-pin structures known as pre-miRNA. Pre-
miRNA are then exported into the cytoplasm where they undergo
further processing into mature miRNA. Mature miRNA involved
in gene silencing are incorporated into RNA-induced silencing
complexes (RISC) (Palanichamy and Rao, 2014). At present, over
17,000 distinct mature miRNAs have been identified in over 140
species (Kozomara and Griffiths-Jones, 2011).
Aberrant expression of miRNAs has been associated with
several human disease states, including cancer, cardiovascular dis-
ease, and genetic disorders (Mendell and Olson, 2012). miRNAs
could be readily employed as biomarkers of exposure and disease
due to the availability of circulating extracellular miRNAs found
in body fluids, such as amniotic fluid, saliva, serum, and plasma.
Additionally, circulating miRNAs have been shown to be corre-
lated with cardiovascular disease and tumors (Mendell andOlson,
2012), suggesting a strong association between detectable levels
and disease.
INCORPORATING METALS-ASSOCIATED EPIGENETIC DATA INTO THE
RISK ASSESSMENT PROCESS
In the present review, epigenetic alterations associated with expo-
sure to the five toxic metals/metalloids inorganic arsenic, cad-
mium, chromium, lead, andmercury are summarized. These data
are examined in order to propose various ways in which the
epigenetic data may be integrated into the human health risk
assessments process. The selection of these prioritized toxic met-
als for this review was based on the 2011 ASTDR Substances
Priority List where they rank in the top five (ATSDR, 2011). In so
far as it is possible, the present review limited studies to human
populations or human cell-derived results in order to maximize
the relevance of the data to risk assessment. While the studies
embodied in this review are by no means completely compre-
hensive, the attempt was to reflect the current state of epigenetic
studies in the literature. In Tables 1–5 studies that have examined
metals-associated epigenetic alterations, including those that were
assessed at a functional level, are summarized.
METALS AND EPIGENETIC ALTERATIONS
ARSENIC EXPOSURE AND ASSOCIATED EPIGENETIC ALTERATIONS
Inorganic arsenic an environmentally ubiquitous toxic metal-
loid (henceforth referred to as a metal) contaminating drinking
water around the globe. Chronic exposure through contaminated
drinking water constitutes a major health concern, and it is esti-
mated that hundreds of millions of individuals are exposed, a
large percentage of which are estimated to exceed the World
Health Organization (WHO) drinking water limit of 10 ppb
(Nordstrom, 2002; WHO, 2006; Centeno et al., 2007).
While a significant research emphasis has been placed upon
the reduction of chronic exposure to arsenic, it is estimated that
millions of individuals continue to be exposed in Bangladesh
alone (Flanagan et al., 2012). Using Bangladesh as a case study,
inorganic arsenic is predicted to contribute significantly to the
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global health burden, based on its associated contribution of over
17,000 disability-adjusted life years (DALYs) and over 9000 deaths
attributed to arsenic-related disease in the country (Lokuge et al.,
2004).
Acute exposure to inorganic arsenic is associated with health
endpoints that include encephalopathy and peripheral neuropa-
thy (Ratnaike, 2003), and chronic exposure is implicated in
cardiovascular, reproductive, respiratory, neurological, diabetic,
and gastrointestinal disorders (WHO, 2006; Das and Sengupta,
2008; Sengupta et al., 2008; Pruss-Ustun et al., 2011). Inorganic
arsenic is classified as a Group 1 human carcinogen (IARC,
1987, 2004) and is associated with kidney, skin, urinary, liver,
and lung cancers (IARC, 2004; WHO, 2006; Straif et al., 2009).
Proposed mechanisms of action in arsenic-mediated carcinogen-
esis are alterations in cellular signaling pathways, perturbations
in the DNA damage response and repair pathways, chromosomal
aberrations, and oxidative stress (Gebel, 2001; Hughes, 2002;
Kligerman and Tennant, 2007; Kitchin andWallace, 2008; Kitchin
and Conolly, 2010).
It is also becoming increasing clear that epigenetic alterations
may play a role in arsenic toxicity and disease. Exposure to inor-
ganic arsenic has been associated with epigenetic modifications
such as changes in global and gene specific DNAmethylation, his-
tone acetylation, methylation, and phosphorylation, and altered
expression of miRNAs. These alterations induced by inorganic
arsenic may contribute to carcinogenesis and non-cancer end-
points (reviewed in Ren et al., 2011; Bailey and Fry, 2014b). While
further study is needed to clearly define the role of epigenetic
alterations in arsenic-associated toxicity and disease, progress
may be made in determining the application of these data to
the risk assessment process utilizing the available epigenetic data.
Studies relating inorganic arsenic exposure and epigenetic modi-
fications are summarized in Table 1.
Arsenic-associated changes in DNA methylation
DNAmethylation is the most commonly studied epigenetic alter-
ation induced by inorganic arsenic. In humans, inorganic arsenic
is biotransformed into its methylated forms; the metabolism pro-
cess converts trivalent arsenite (iAsIII) and pentavalent arsenate
(iAsV) to trivalent and pentavalent methylated forms. The pri-
mary enzyme involved in the required reduction and methylation
reactions is arsenic methyltransferase (AS3MT), which utilizes
SAM as a methyl donor (Thomas et al., 2004, 2007; Drobna
et al., 2009). DNAmethylation and biotransformation of iAs both
employ SAM as a methyl donor. While a trend of hypomethyla-
tion is seen, the effect of arsenic-induced SAM depletion on DNA
methylation is inconclusive (Zhao et al., 1997; Reichard et al.,
2007; Coppin et al., 2008; Nohara et al., 2011). The activity of
DNMT, the primary enzymemediating DNAmethylation, is gen-
erally decreased upon exposure to inorganic arsenic, though the
exact mechanisms are unknown (Zhao et al., 1997; Cui et al.,
2006b; Fu et al., 2010). The majority of studies report that arsenic
induces global DNA hypomethylation; however, instances have
been reported of arsenic inducing global hypermethylation (Mass
and Wang, 1997; Davis et al., 2000). Of note is that biotransfor-
mation of iAs is not essential for DNA hypomethylation (Coppin
et al., 2008).
Genome-wide DNA hypermethylation was observed in
peripheral blood leukocytes from arsenic exposed individuals in
India and Bangladesh (Pilsner et al., 2007, 2009b; Majumdar
et al., 2010). DNA hypermethylation has been observed in
a dose-dependent manner, but only in the presence of ade-
quate folate (Pilsner et al., 2007). Interestingly, increased risk of
arsenic-related skin lesions was associated with DNA hypomethy-
lation (Pilsner et al., 2009b). This is important as global
hypomethylation has been implicated in carcinogenesis (Eden
et al., 2003;Wilson et al., 2007). In addition to genome-wide DNA
methylation, gene specific DNA methylation in human popula-
tions has also been demonstrated. DNAmethylation of the tumor
suppressor cyclin-dependent kinase inhibitor 2A (CDKN2A/p16)
promoter has been positively associated with arsenic exposure in
individuals from West Bengal, India (Chanda et al., 2006) and
Guizhou, China (Zhang et al., 2007). However, no relationship
between arsenic exposure and methylation of the CDKN2A/p16
promoter was found in a study conducted in New Hampshire
(Marsit et al., 2006a). In urothelial carcinomas, promoter methy-
lation of tumor suppressors protease serine 3 (Homo sapiens;
PRSS3) and Ras association (RalGDS/AF-6) domain family mem-
ber 1 (RASSF1A) (Marsit et al., 2006a) and death-associated
protein kinase 1 (DAPK) (Chen et al., 2007) was correlated with
arsenic exposure between individuals exposed and not exposed
from New Hampshire and Taiwan.
Arsenic exposure alters DNA methylation of genes involved in
tumorigenesis (reviewed in Bailey and Fry, 2014a). Tumor sup-
pressor genes that are methylated in response to arsenic exposure
include CDKN2A (Davis et al., 2000), tumor protein 53 (TP53)
(Mass and Wang, 1997; Davis et al., 2000), von Hippel–Lindau
tumor suppressor (VHL) (Zhong andMass, 2001), RASSF1A (Cui
et al., 2006a), DAPK (Chai et al., 2007), and reversion-inducing-
cysteine-rich protein with kazal motifs (RECK) (Huang et al.,
2011). DNA methylation of oncogenes in response to arsenic
include cyclin D1 (CCND1) (Chen et al., 2004), estrogen recep-
tor alpha (ER-α) (Chen et al., 2004; Waalkes et al., 2004) and
members of the RAS family of small G-proteins such asHRAS and
KRAS (Benbrahim-Tallaa et al., 2005). Our group identified 183
differentially methylated promoters associated with arsenic expo-
sure in adult subjects from Zimapan, Hildago, Mexico (Smeester
et al., 2011), and out of this group were 17 tumor suppres-
sor or tumor suppressor-associated genes with hypermethylated
promoters.
As seen in human populations, in vitro studies also demon-
strate inorganic arsenic-induced changes in DNA methylation
status of promoter regions. For example, arsenic trioxide treat-
ment of malignant cell lines decreased hypermethylation of
RASSF1A, p16, GSTP1 (Cui et al., 2006b), and cyclin dependent
kinase 2A/2B (CDKN2A/CDKN2B; p16/p15) (Fu et al., 2010) pro-
moters and concomitantly increased expression of mRNA levels
of these genes. Increased arsenic exposure induces DNA hyper-
and hypomethylation of regions of the genome relative to unex-
posed cells in human kidney and lung cell lines (Zhong and
Mass, 2001), and in arsenic transformed human urothelial cell
lines (Jensen et al., 2009a). Also of interest to risk assessment
is that focal DNA methylation patterns are stable events that
exist in arsenic-transformed cells even after arsenic exposure has
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ceased (Jensen et al., 2009a). Similar observations of correlations
between focal DNA methylation and gene expression have been
reported in iAsIII- and MMAIII-transformed human urothelial
cells. An inverse relationship between mRNA levels and DNA
hypermethylation of promoters was reported for C1q and tumor
necrosis factor related protein 6 (C1QTNF6), deleted in bladder
cancer 1 (DBC1), G0/G1switch 2 (G0S2), family with sequence
similarity 83, member A (FAM83A), keratin 7 (KRT7), zinc
finger and SCAN domain containing 12 (ZSCAN12), epireg-
ulin (EREG), and thioesterase superfamily member 4 (THEM4)
(Jensen et al., 2008, 2009a).
Proper development of the fetus is dependent upon establish-
ment of fetal DNA methylation patterns, which can influence
the health of individuals even into adulthood (reviewed in Kim
et al., 2009). Alterations in DNA methylation patterns associ-
ated with in utero exposure may influence the expression of
genes/proteins involved in key signaling pathways that underlie
adverse health outcomes associated with gestational arsenic expo-
sure. Thus, the study of alterations in DNA methylation profiles
in response to gestational arsenic exposure is an area of great
interest.
Arsenic-associated changes in histone modifications
Chervona et al. demonstrated that in individuals exposed to inor-
ganic arsenic in Bangladesh, total urinary arsenic was inversely
correlated with global H3K9Ac and positively correlated with
H3K9me2 (Chervona and Costa, 2012). In addition gender spe-
cific differences were found with a positive correlation between
well water arsenic and global H3K4me3 and H3K27me3 in
females and a negative correlation between males (Chervona
et al., 2012), demonstrating the viability of associating arsenic
exposure and histone modifications in human populations. An
additional study showed that histone modifications were associ-
ated with arsenic in steel workers exposed to particulate matter
(PM) containing arsenic. A positive correlation was reported
between H3K4me2 and H3K9Ac and cumulative exposure to
arsenic and nickel-containing PM in peripheral blood lympho-
cytes (PBL) (Cantone et al., 2011). Given the broad range of
histone modifications induced by inorganic arsenic in cultured
human cell lines, further exploration of histone modifications
in humans exposed to arsenic is warranted. Exploration of the
relationship between arsenic-induced histone modifications and
diseases associated with chronic arsenic exposure would be of
great value for risk assessment. The majority of histone mod-
ifications associated with arsenic exposure, however, has been
demonstrated in vitro.
Huang et al. demonstrated that arsenic induces the expres-
sion of the anti-oxidant gene ferritin through methylation of
H4 arginine 3 (H4R3) and H3 arginine 17 (H3R17) in a dose-
dependent manner in human keratinocytes (Huang et al., 2013).
Transient knockdown of the methyltransferases PRMT1 and
PRMT4 resulted in decreased histone methylation and ferritin
expression; most interesting was the decrease in the transcrip-
tion factor Nrf2 binding to the ferritin promoter (Huang et al.,
2013). This suggests that arsenic induces transcription factor
recruitment and promoter binding through histone methyla-
tion. Arsenic is also a potent inducer of H3S10 phosphorylation
(H3S10p), and this event has been associated with up-regulation
of genes involved in tumorigenesis (Li et al., 2003). Ablation of
H3S10p through chemical inhibition, kinase knockdown, or the
use of a transfected histone H3S10A mutant results in decreased
cell transformation in several models (Choi et al., 2005, 2008a;
Zippo et al., 2007; Kim et al., 2008). These data suggest a possible
association between arsenic exposure, histone phosphorylation,
and carcinogenesis. At extremely high concentrations, inorganic
arsenic induces a DNA damage response, and so was found to
induce H2AX phosphorylation in the context of DNA damage
and apoptosis (Yih et al., 2005; Zykova et al., 2006).
Arsenic exposure induces global and focal histone acetylation
and methylation in human cell lines (Ramirez et al., 2008; Zhou
et al., 2008, 2009; Jo et al., 2009; Chu et al., 2011). Arsenite modu-
lates global H4K16Ac (Ramirez et al., 2008; Jo et al., 2009) as well
as heterochromatic-specific H3K4me2 and euchromatic-specific
H3K4me3 increases (Zhou et al., 2009). Histone acetylation by
arsenic is also gene specific; H3 phosphoacetylation by arsenic
was associated with upregulation of caspase 10, apoptosis-related
cysteine peptidase (CASP10), and the proto-oncogenes C-Jun and
C-Fos (Li et al., 2002, 2003). Differential H3 acetylation of several
promoters was reported in arsenic transformed urothelial cells
compared to untransformed cells (Jensen et al., 2008). mRNA
expression of the hypoacetylated FAM83A, DBC1, C1QTNF6,
and ZSCAN12 genes, as well as the hyperacetylated neurofila-
ment, light polypeptide (NEFL) gene was analyzed; there was
a positive correlation between mRNA levels and H3 acetylation
(Jensen et al., 2008). Crosstalk between histone modifications and
DNA methylation has been reported, as a correlation was found
between DNA hypermethylation and H3 hypoacetylation at the
promoters of FAM83A, ZSCAN12, C1QTNF6, and DBC1 (Jensen
et al., 2008, 2009a). Another study demonstrated that histone
modifications play a major role in gene expression implicated in
As-mediated carcinogenesis (Jensen et al., 2009b). WNT5A was
identified as a key player in arsenic-induced malignant transfor-
mation of human urothelial cells. In turn, WNT5A expression
was regulated by permissive and repressive histone modifications,
most notably H3K27 methylation and H3 acetylation. The lat-
ter was shown to be stable as it was maintained after malignant
transformation and withdrawal of arsenic exposure (Jensen et al.,
2009b).
Several studies have demonstrated the mechanisms of arsenic-
induced histone modifications, focusing on the expression and
activity of histone modifying enzymes. Increases in H3K9 acety-
lation by arsenic in hepatocellular carcinoma cells was correlated
with inhibition of HDAC activity (Ramirez et al., 2008). In
human lung A549 cells, arsenic was shown to increase H3K9
di- and tri-methylation through increased expression of the
H3K9 methyltransferase G9a; however there was no change in
expression of lysine (K)-specific demethylase 3A (JHDM2A),
the major demethylase involved in H3K9 dimethylation (Zhou
et al., 2008). These studies demonstrate the broad range of
histone modifications induced by inorganic arsenic exposure
in the context of the expression of genes associated with
arsenic-mediated diseases. There is the possibility that these
genes represent possible biomarkers of inorganic arsenic-induced
disease.
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Arsenic-associated changes in miRNA expression
In human lymphoblasts, arsenic altered the expression of five
miRNAs; miR-221, miR-222, miR-210, miR-34a, and miR-22
(Marsit et al., 2006b). The biological roles of miRNAs in cells
exposed to arsenic have also been investigated. miR-29a was
associated with arsenic-mediated apoptosis in hepatocellular car-
cinoma cells (Meng et al., 2011) as well as miR-19a in human
bladder carcinoma cells (Cao et al., 2011).
Malignant transformation of TP53−/− cells in response to
arsenic treatment was correlated with decreased levels of miR200b
(Wang et al., 2011). Decreased expression of miR200b occurred
concomitantly with methylation of the miR-200 promoter, sug-
gesting that arsenic may transcriptionally repress miRNA expres-
sion through DNAmethylation (Wang et al., 2011). These studies
demonstrate the role of specific miRNAs in arsenic-mediated
tumorigenesis, thus serving as possible key biomarkers for disease
risk.
Epigenetic data in the arsenic risk assessment process
As a specific example demonstrating how arsenic-associated
epigenetic modifications may inform the risk assessment pro-
cess, we considered DNA methylation patterning in response to
arsenic exposure. Specifically this was considered in the context
of the second step in the risk assessment process, namely the
dose-response assessment. A study of Bangladeshi adults with
chronic exposure to arsenic via contaminated drinking water
demonstrated dose-responsive global hypermethylation of DNA
in peripheral blood leukocytes (Pilsner et al., 2007). In a separate
study, dose-responsive DNA hypermethylation of the tumor sup-
pressors TP53 and TP16 was observed among individuals with
chronic exposure to arsenic in West Bengal, India compared with
control individuals (Chanda et al., 2006). These findings imply
that DNA methylation observed in these studies is dose respon-
sive with arsenic exposure and thus may help to inform the
dose-response assessment step. In combination with studies that
have found associations between arsenic-induced DNA methy-
lation patterns and negative health endpoints (as reviewed in
Tseng, 2007), these findings may also ultimately aid in inform-
ing the hazard identification step as well. The integration of
dose-dependent changes in epigenetic profiling with functional
changes in gene/protein expression will be needed to fill in
knowledge gaps related to the dose-dependent relationships.
MERCURY EXPOSURE AND ASSOCIATED EPIGENETIC ALTERATIONS
Mercury is ranked third by the ATSDR (2011) Substance Priority
List (ATSDR, 2011) and is listed as one of the WHO’s top 10
chemicals of major public health concern (WHO, 2003). This
ubiquitous element is found in the earth’s crust and is released
into the air by natural geological phenomena such as volcanic
eruptions and oceanic evaporation following weathering of the
crust. Humans are primarily exposed to mercury through occu-
pational exposure including metal smelting, gold mining, coal
burning, electric industries, and wood production; dietary expo-
sure from seafood; and ambient air exposure from the burning
of fossil fuels and evaporation from mercury contaminated waste
(reviewed in Boening, 2000; Tchounwou et al., 2003; Spiegel,
2009). It is estimated that as developing countries make the
transition to heavy industrialization, increasing levels of mer-
cury will be introduced into the air, which may lead to greater
inhalation and dietary exposure (Zhang et al., 2002; UNEP, 2013).
Mercury occurs in a variety of forms including the elemen-
tal form, inorganic mercury, and organic mercury salts, which
includes the highly toxic methylmercury (MeHg). Although
exposure differs dramatically based on location, occupation, and
diet, the 2009 National Health and Nutrition Examination Study
(NHANES), estimates that ∼2% of American women of repro-
ductive age exceed the oral RfD for mercury (EPA, 2013). This is
particularly disconcerting, as a number of studies have shown that
MeHg readily crosses the placenta, and in-utero exposure is asso-
ciated with a host of negative health outcomes including learning
disabilities, reduced cognitive function, immune suppression, and
a host of neurological disorders (reviewed in Zahir et al., 2005;
Holmes et al., 2009; Park and Zheng, 2012). In children and
adults, mercury exposure has been associated with negative health
outcomes in cardiovascular systems, respiratory systems, neuro-
logical systems, as well as changes in the thyroid, liver, kidney,
and immune function (reviewed in Counter and Buchanan, 2004;
Holmes et al., 2009). In addition to exposure of vulnerable pop-
ulations such as children and the developing fetus, acute and
chronic exposure is predicted to afflict untold numbers of indi-
viduals worldwide, and continues to contribute to the global
burden of disease. To date, few human studies have explored the
epigenetic alterations induced by mercury. Studies relating expo-
sure to mercury and epigenetic alterations are summarized in
Table 2.
Mercury-associated changes in DNA methylation
Currently, few human studies have investigated changes in DNA
methylation patterns related to environmental mercury exposure.
One study found increased methylation of the promoter region of
glutathione S-transferase mu 1 (GSTM1) in women with elevated
blood mercury levels (above 2.9μg/L). However, no statistical
correlation was found and the study did not ascertain GSTM1
expression levels (Hanna et al., 2012). Another study measured
mercury exposure in hair samples and found that for males there
was a correlation between DNA hypomethylation of the seleno-
protein P plasma 1 (SEPP1) promoter and increasing mercury
levels (Goodrich et al., 2013). As in the former study, expression
levels of SEPP1 were not investigated. Both genes in these two
studies are involved in the cellular antioxidant response system,
which mitigates oxidative stress. Though gene expression was not
measured in these two cases, there is the potential that DNA
methylation of the promoters would influence their expression
and thus alter the oxidative stress response.
Mercury-associated changes in histone modifications
At present, the majority of investigations into histone mod-
ification resulting from exposure to environmental mercury
or its compounds have been conducted in non-human stud-
ies. In mouse models, exposure to MeHg was associated
with increased H3K27 trimethylation (H3K27m3) along with
decreased histone H3 acetylation in the promoter region of
brain derived neurotrophic factor (BDNF) (Onishchenko et al.,
2008). Another group investigating mouse embryonic stem cells
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found exposure to mercury chloride (HgCl2) decreased total his-
tone protein (THP) and was associated with decreased H3K27
mono-methylation (Gadhia et al., 2012). Given the conservation
of cellular responses in mice to humans and the effect of other
metals on histone modifications in humans, it may be predicted
that mercury also induces histone modification in humans.
Mercury-associated changes in miRNA expression
In carcinoma pluripotent stem cells, exposure to methyl mercury
chloride (MeHgCl) was associated with increased expression of
miR-302b, miR-367, miR-372, miR-196b, and miR-141 (Pallocca
et al., 2013). It was shown that these miRNAs were associated
with developmental processes and cellular responses to stress,
and pathway analysis on possible mRNA targets revealed pos-
sible links to neurological development including learning and
memory formation.
Epigenetic data in the mercury risk assessment process
The few human studies investigating epigenetic alterations related
to mercury exposure may be considered as examples of epige-
netic alterations useful to inform the risk assessment process.
Specifically, it was demonstrated that increasing mercury levels
were correlated with DNA hypomethylation of the SEPP1 pro-
moter (Goodrich et al., 2013); these data provide a foundation
that could eventually inform the dose-response step of the risk
assessment process. Correlations between metal-responsive epi-
genetic alterations and signaling pathways involved in disease
could also inform the hazard identification step. For example,
it was demonstrated that mercury-mediated induction of miR-
NAs may be involved in the regulation of pathways involved
in stress response (Pallocca et al., 2013). Still, additional data
are needed to provide causal links between miRNA induc-
tion by metals with metal-mediated alterations in cellular stress
response signaling pathways. This provides a starting point
by which information on miRNA modulation may be intro-
duced into the hazard identification step of the risk assessment
process.
LEAD EXPOSURE AND ASSOCIATED EPIGENETIC ALTERATIONS
Lead is a naturally occurring element that is widely known for
its human health impacts. Low levels of exposure has been pri-
marily associated with adverse effects in the nervous (Finkelstein
et al., 1998), immune (Mishra, 2009), cardiovascular (Navas-
Acien et al., 2007), and renal systems (Kim et al., 1996), as well
as a reduction in male fertility (Sallmen, 2001), negative preg-
nancy outcomes (Juberg et al., 1997; Xie et al., 2013), behavior
problems (Bellinger et al., 1994), impaired cognitive function
(Canfield et al., 2003), lowered IQ scores (Nevin, 2000; Canfield
et al., 2003), and violence (Stretesky and Lynch, 2001; Olympio
et al., 2009). These effects have been associated with both chronic
and acute exposure, and have been linked to exposure in the
womb or during childhood (reviewed in Flora, 2002). Known
primarily for effects in the neurological development of chil-
dren, prenatal and childhood exposure to lead has been shown
to reduce cognitive function at both high (Bellinger et al., 1987)
and low doses (reviewed in Lanphear et al., 2005; Jedrychowski
et al., 2009). Exposure to the metal or its salts primarily occurs
through inhalation or ingestion (reviewed in Tong et al., 2000;
Moreira and Moreira, 2004).
Considerable public health action has been undertaken in
the regulation of lead in gasoline (Nriagu, 1990), paint (Farfel
and Chisolm, 1990), and piping (Wong and Berrang, 1976) that
has been effective in reducing blood lead levels (BLLs) in the
United States (Pirkle et al., 1994; Muntner et al., 2005). However,
exposure to lead continues to be a problem both in the United
States and worldwide (Warniment et al., 2010), with almost a
half million children exceeding the Center for Disease Control
and Prevention (CDC) level of concern of 5μl/dl (CDC, 2013),
although at present there is no safe BLL (CDC, 2012). Worldwide,
the poisonous element is estimated to contribute almost 0.6% to
the global burden of disease, and as of 2000, an estimated 240
million individuals had BLLs above 5μl/dl (WHO, 2000). While
the mechanism of action for lead’s long term neurological effects
are still not completely understood, it is suspected that the for-
mation of reactive oxygen species, altered gene expression, and
changes to calcium signaling may play a role in the pathogene-
sis of lead-associated disease (reviewed in Sanders et al., 2009).
Studies relating lead exposure and epigenetic modifications are
summarized in Table 3.
Lead-associated changes in DNA methylation
To date, few studies have been conducted to assess associations
between DNA methylation and lead exposure. The studies that
have been conducted tend to focus onmeasures of global genomic
methylation, such as measuring Alu or long interspersed nuclear
elements-1 (LINE-1) (Yang et al., 2004). In one study, mater-
nal tibia lead levels were shown to have an inverse association
with methylation of Alu and LINE-1 in newborns (Pilsner et al.,
2009a). No association was noted between cord BLLs of methy-
lation of Alu and Line-1. However, in a separate study conducted
with an older cohort, tibia lead levels were not correlated with
LINE-1 or Alu methylation, and were not predictive of global
methylation levels (Wright et al., 2010). The same study did
find patella lead levels had an inverse correlation with methyla-
tion of LINE-1, but not Alu methylation. Based on these results,
it is theorized that historical exposure captured in the patella
is associated with decreased methylation of LINE-1 elements,
whereas more recent exposure captured in the tibia is associated
with decreased methylation of both LINE-1 and Alu in infants
(Wright et al., 2010). In the context of the early life exposures,
such results imply that the one of the most vulnerable pop-
ulations, developing fetuses, may experience changes in global
methylation as a result of historical maternal lead exposure and
accumulation.
In women seeking in vitro fertilization (IVF), there was
an inverse association between lead exposure and methylation
of the promoter region of the gene Collagen Type I, Alpha
2 (COL1A2) (Hanna et al., 2012). In a separate study, indi-
viduals with high blood lead concentrations had methylation
of the tumor suppressor, CDKN2A/TP16, whereas individuals
with low blood lead concentrations only had partial methy-
lation of TP16 (Kovatsi et al., 2010). In another study, cells
from the carcinoma cell line A431 were exposed to lead ions
(Pb2+) which lead to a reduction in methylation of the gene
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prostaglandin-endoperoxide synthase 2 (PTGS2) (Tsai et al.,
2014).
At present, additional research is needed to detail the mech-
anisms underlying the relationship between lead exposure and
altered levels of DNA methylation. It has been theorized that
the generation of reactive oxygen species may inhibit the bind-
ing of methyl-CpG binding proteins and ultimately change the
functionality of DNA methyltransferase (Pilsner et al., 2009a).
Additionally, exposure to lead in in vitro models of human
neuroblastoma cells inhibited the activity of IGF-1, which acts
directly on methionine synthase (Waly et al., 2004). Methionine
synthase is one of many enzymes crucial in the regulation of DNA
methylation, and disruption of normal enzymatic levels by inhibi-
tion of IGF-1 may present another possible pathway linking lead
exposure and methylation. While addition research is needed, it
is clear that individuals, children, and developing fetuses may
experience global, or site specific methylation in response to envi-
ronmental lead exposure. In the event that these changes in DNA
methylation are associated with functional changes in gene and
protein expression, they may present a viable mode of action
to explain some of lead’s toxicity and related negative health
outcomes.
Lead-associated changes in histone modifications
Currently, to our knowledge, no human studies have investigated
histone modification resulting from exposure to environmental
lead. However, researchers studying primate models have found a
reduction in proteins associated with histone modification linked
to infant lead exposure (Bihaqi et al., 2011).
Lead-associated changes in miRNA expression
As with histone modification, the field of miRNA changes as
a result of environmental lead exposure is sparse. At present,
only one study has investigated changes in miRNA expression
in response to lead. The study, conducted on peripheral blood
leukocytes exposed via inhalation, found miR-222 expression
showed a positive association with lead exposure, while miR-
146a expression was negatively correlated with lead exposure
(Bollati et al., 2010). miR-146a, which was down regulated, has
been shown to be associated with inflammation in rodent mod-
els (Boldin et al., 2011), and is predicted to play a role in the
innate immune response (Taganov et al., 2006). miR-222, which
had increased expression due to lead exposure has been shown to
regulate the tumor suppressor, Cyclin-dependent kinase inhibitor
1B (p27Kip1), and down regulation of p26Kip1 has been linked
to increased cell proliferation and higher incidences of various
cancers (Le Sage et al., 2007).
Epigenetic data in the lead risk assessment process
While the adverse health effects of high dose lead exposure have
been known for some time, studies have found that previously
labeled “safe” levels of lead may be associated with negative
health outcomes (Lanphear et al., 2005; Zhang et al., 2013), thus
necessitating additional lead risk assessments. The use of data
on lead-mediated epigenetic alterations may help to inform the
hazard identification step of the lead risk assessment process.
One study demonstrated that lead exposure as measured by
maternal tibia and patella samples, was correlated with global
DNA hypomethylation in umbilical cord blood (Pilsner et al.,
2009a). A separate study demonstrated in a cohort of older indi-
viduals that patella lead levels were associated with global DNA
hypomethylation (Wright et al., 2010). Such findings can aid in
determining the risk of fetal adverse health outcomes in response
to maternal lead exposure. These studies also increase the under-
standing of lead’s mechanisms of action, and may ultimately
be useful as alternative measures for historical or cumulative
biomarkers of exposure. These results may help to inform the haz-
ard identification process particularly if the results can be linked
to health endpoints resulting from decreased global DNA methy-
lation, especially during embryonic development. Ultimately,
such results may help to link additional health outcomes to
current biologically relevant exposures.
CADMIUM EXPOSURE AND ASSOCIATED EPIGENETIC ALTERATIONS
Cadmium is an environmental contaminant associated with con-
siderable global disease burden. Exposure to cadmium occurs
primarily through cigarette smoke and dietary sources (reviewed
in ATSDR, 2008; Jarup and Akesson, 2009). Present in almost
all foods, levels of cadmium vary greatly depending upon the
type of food and source contamination; high concentrations are
found in crustaceans, mollusks, and offal meats such as the liver
and kidney. However, plant matter such as leafy green vegeta-
bles and root vegetables contain higher cadmium levels than do
meat (Jarup and Akesson, 2009). Cadmium has a long half-life in
humans; specifically 10–30 years in the kidney, which is the main
target organ of cadmium toxicity in response to chronic dietary
exposure (Godt et al., 2006). In addition to renal toxicity, cad-
mium exerts toxicity on bone, and is associated with osteoporosis
and osteomalacia (“Itai Itai” disease of Japan). Unlike other toxic
metals, cadmium is a partial transplacental agent and accumulates
in the placenta and has been implicated in adverse birth outcomes
(Kippler et al., 2012).
Cadmium is classified as a Group I carcinogen, associated with
cancers of the liver, bone, kidney, and pancreas as well as a known
risk factor for cardiovascular disease (reviewed in ATSDR, 2008;
Jarup and Akesson, 2009; Tellez-Plaza et al., 2012). Our lab has
demonstrated that low dose cadmium exposure in human lym-
phoblast cells alters the expression of genes involved in various
biological functions including cancer and cardiovascular disease
(Benton et al., 2011). Suggested mechanisms of action of cad-
mium exposure include inhibition of DNA repair, generation of
reactive oxygen species, and perturbation of cell cycle progression
or apoptosis (Waisberg et al., 2003). As with other toxic metals
prioritized in this review, the effect of cadmium on gene expres-
sion has been studied, while the impact of cadmium on changes
to epigenetic machinery is largely under studied. Given the expo-
sure levels and resulting toxicity, it is increasingly clear that studies
detailing the epigenetic effects of cadmium on toxicity and disease
are warranted. Studies relating cadmium exposure and epigenetic
alterations are summarized in Table 4.
Cadmium-associated changes in DNA methylation
In humans, prenatal cadmium exposure has been associated with
altered DNA methylation in blood leukocytes (Sanders et al.,
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2014). These patterns of DNA methylation displayed an enrich-
ment for binding sites of specific transcription factors and were
thus hypothesized to represent an “environmental footprint” of
transcription factor occupancy during times of DNAmethylation
(Sanders et al., 2014).
Several in vitro studies have correlated changes in DNAmethy-
lation and features of the carcinogenesis process in response to
cadmium. Differential DNAmethylation profiles in immortalized
cells lines transformed by chronic cadmium exposure were also
seen in established cancer cell lines as well as primary tumor tis-
sues (Severson et al., 2012). These results suggest that cadmium-
associated cancers may share DNA methylation signatures and
these signatures may serve as biomarkers in the risk assessment
process. In the context of cadmium carcinogenesis, it was shown
that cadmium induces cell proliferation in K562 cells concomi-
tantly with global DNA hypomethylation. Interestingly, pretreat-
ment with methionine not only abrogated the hypomethylation
effect but cell proliferation was well, suggesting that cadmium
may induce cell proliferation by decreasing DNA methylation
levels (Huang et al., 2008). In cadmium-induced malignant
transformation of prostate epithelial cells, DNA hypermethy-
lation was associated with silencing of the tumor suppressor
genes TP16 and RASSF1A through cadmium-mediated overex-
pression of DNMT3b (Benbrahim-Tallaa et al., 2007), but not
DNMT1. However, another study conducted in human lung
fibroblasts chronically exposed for a period of 2 months showed
that cadmium increased mRNA expression of DNMT1, as well as
DNMT3a and DNMT3b, and this corresponded to an increase in
global DNA hypermethylation (Jiang et al., 2008). The increases
in methyltransferase expression and DNA methylation were dose
dependent, and thus may be useful in the risk assessment pro-
cess. In cadmium-transformed human bronchial epithelial cells,
promoter hypermethylation resulted in decreased expression of
the DNA repair genes MutS homolog 2 (MSH2), excision repair
cross-complementation group 1 (ERCC1), X-ray repair comple-
menting defective repair 1 (XRCC1), and 8-oxoguanine DNA
glycosylase (OGG1) (Zhou et al., 2012). Hypermethylation and
gene silencing was associated with overexpression ofDNMT1 and
DNMT3a. Furthermore, inhibition of DNA methylation reversed
the decrease in DNA repair enzyme expression. These three stud-
ies collectively demonstrate that cadmium silences tumor sup-
pressor and DNA repair genes through DNA hypermethylation
mediated by increased expression of DNA methyltransferases.
Cadmium is a known endocrine disruptor, and in immor-
talized trophoblasts cadmium increased expression of hydroxys-
teroid (11-beta) dehydrogenase 2 (HSD11B2),which regulates the
steroid hormone cortisol. This increase in expression was associ-
ated with DNA hypomethylation of the HSD11B2 gene, suggest-
ing epigenetic mechanisms in cadmium-mediated reproductive
toxicity (Ronco et al., 2010).
Cadmium-associated changes in histone modifications
Reports of cadmium-induced histone modifications are mainly
limited to in vitro studies. In cadmium-transformed urothe-
lial cells, levels of H3K4me3, H3K27me3, and H3K9me3 occu-
pancy at the metallothionein 3 (MT3) promoter were increased
compared to untransformed cells, suggesting chronic cadmium
exposure may alter transcriptional responses through histone
modification (Somji et al., 2011). MT3 silenced in untransformed
UROtsa cells, was expressed after cadmium transformation and
this was mediated bymetal transcription factor 1 (MTF1) binding
to a metallothionein (MT) metal responsive element (MRE); of
special interest was that MTF1 binding was significantly increased
in the presence of a HDAC inhibitor, suggesting that histonemod-
ification in cadmium-transformed cells is necessary for maximal
transcription factor binding and gene activation (Somji et al.,
2011). In addition to altering methylation of histone H3 lysine
residues, cadmium was shown in vitro to decrease H3 auto-
phosphorylation by inhibition of the human vaccinia-related
kinase VRK1/2 (Barcia-Sanjurjo et al., 2013), demonstrating that
cadmium may block histone modifications through inhibition of
histone modifying enzymes.
Cadmium-associated changes in miRNA expression
Peripheral blood leukocytes from workers at an electric fur-
nace steel plant were analyzed after 3 days of exposure to PM
containing cadmium; while the expression ofmiR-146a in periph-
eral blood leukocytes was not statistically increased in exposed
vs. baseline leukocytes, miR-146a was negatively correlated with
occupational cadmium exposure (Bollati et al., 2010). Cadmium
has been shown to alter miRNA levels in vitro. In a human hep-
atocellular carcinoma cell line, miRNA expression was analyzed
after cadmium exposure; several differentially expressed miRNAs
were members of the let-7 family, which exhibits oncogene silenc-
ing functions (Fabbri et al., 2012). In studying the role of airway
pollutants in cystic fibrosis, Hassan et al. showed that cadmium
decreased expression of the cystic fibrosis transmembrane con-
ductance regulator (CFTR) in human bronchial epithelial cells
(Hassan et al., 2012). CFTR is a predicted target of miR-101 and
miR-144, and this group further demonstrated that cadmium
upregulates the expression of miR-101 and miR-144 (Hassan
et al., 2012), suggesting that cadmium, through miRNA induc-
tion, may be involved in the pathogenesis of cystic fibrosis. These
latter two studies implicate cadmium in two disparate disease
states through alterations of miRNA levels and such alterations
may be useful in the risk characterization step.
Epigenetic data in the cadmium risk assessment process
In relation to the risk assessment process, cadmium has been
shown to silence the expression of DNA repair enzymes and
tumor suppressor genes in a dose-dependent manner via
DNA hypermethylation. Specifically this was associated with
an increase in the expression of DNMT family members
(Benbrahim-Tallaa et al., 2007; Jiang et al., 2008; Zhou et al.,
2012). These data can be applied to the dose-response assessment
and hazard identification steps of the risk assessment process,
given that silencing of these genes represent key factors in carcino-
genesis. DNA methylation induced by cadmium may contribute
to the current understanding of cadmium’s toxicity as it relates to
chronic or acute exposures. Chronic exposure of human cell lines
to cadmium induced global DNA hypermethylation (Benbrahim-
Tallaa et al., 2007; Jiang et al., 2008; Severson et al., 2012; Zhou
et al., 2012); however, acute exposure to cadmium was associ-
ated with global DNA hypomethylation in other immortalized
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cell lines (Huang et al., 2008; Ronco et al., 2010). As both global
hyper and hypomethylation are associated with a range of diseases
(Robertson, 2005; Wilson et al., 2007), these varied epigenetic
effects associated with either acute or chronic exposure may help
to elucidate possible mode of action differences between varied
exposure paradigms. As a result, such epigenetic data may be
employed to predict adverse health outcomes based on length of
cadmium exposure.
CHROMIUM EXPOSURE AND ASSOCIATED EPIGENETIC ALTERATIONS
Chromium is utilized in several industrial applications from
chrome plating and welding to leather tanning and stainless steel
manufacturing (reviewed in Zhitkovich, 2011). However, the bulk
of human exposure is mainly through drinking water contami-
nated through industrial chromium use. Hexavalent chromium
(henceforth referred to as chromium except where noted) is
highly mutagenic and associated with a wide array of cancers
including prostate, bone, leukemia, lymphoma, renal, gastroin-
testinal, brain, and lung cancer (Langard, 1990). The mutagenic
and carcinogenic nature of chromiummay be explained in part by
the variety of genotoxic lesions that it produces; chromium forms
adducts with DNA, induces DNA strand breaks, DNA intra- and
interstrand crosslinks, and DNA-protein crosslinking (Shi and
Dalal, 1994; Stearns et al., 1995; Zhitkovich, 2005). Chromium
also interferes with DNA damage response and repair. A proposed
mechanism of action of chromium toxicity is the generation of
reactive oxygen species, which are generated during the cellular
reduction of hexavalent chromium to intermediate species (Shi
and Dalal, 1994). Studies relating exposure to chromium and
epigenetic modifications are summarized in Table 5.
Chromium-associated changes in DNA methylation
The effect of chromium exposure on DNAmethylation in human
populations has been documented; in a study investigating the
effect of folate deficiency on chromium-induced DNA damage,
red blood cells of industrial chromate workers were analyzed and
showed that chromium exposure was correlated with global DNA
hypomethylation, decreased folate levels, and increased oxidative
DNA damage (Wang et al., 2012). DNA methylation alterations
in lung tumors have been associated with chromium exposure.
Kondo and Takahashi et al. studied the methylation status of
tumor suppressor and DNA repair genes in chromium vs. non-
chromium lung tumors from workers exposed to chromium;
lung tumors of chromium exposed workers showed a correla-
tion between the hypermethylation of TP16 and human mutL
homolog 1 (hMLH1) promoters and the silencing of their expres-
sion (Takahashi et al., 2005; Kondo et al., 2006). Lung tumors of
workers exposed to chromium showed differential DNA hyper-
methylation of tumor suppressor genes MGMT and APC pro-
moters as compared to lung tumors of subjects not exposed to
chromium (Ali et al., 2011).
In cell culture models, global DNA hypomethylation was
induced by chromium in A549 lung cells and B lymphoblastoid
cells in the context of cell cycle arrest (Lou et al., 2013). While
expression of TP16, CDK4, and CDK6 mRNA levels were altered
in response to chromium, DNA methylation levels at the TP16
promoter did not change, suggesting that chromium regulates
TP16 and cell cycle progression independently of promoter spe-
cific DNA methylation (Lou et al., 2013). Ding et al. investigated
whether DNA methylation regulated repression of E-cadherin in
oncogenic transformation, but found that chemical inhibitors of
DNA methylation had no effect on E-cadherin expression in lung
epithelial cells (Ding et al., 2013). Taken together these data sug-
gest that caution should be taken in interpreting the effect of
DNA methylation on chromium regulated expression of genes
involved in carcinogenesis given the discrepancy between in vivo
and in vitro studies.
Chromium-associated changes in histone modifications
It has been demonstrated in vitro that chromium interacts
with histone arginine and lysine residues (Levina et al., 2006).
Chromium induces phosphorylation of histone H2AX in con-
junction with DNA damage (Vilcheck et al., 2006). Chromium
may regulate histone biotinylation. In bronchial epithelial cells,
hexavalent chromium was shown to decrease expression of bio-
tinidase, an enzyme involved in the histone biotinylation pathway,
and this transcriptional event was reversed in the presence of
HDAC inhibitors suggesting a role for histone acetylation (Xia
et al., 2011). Based on the study, chromium may induce changes
in histone modification through altering expression of histone-
modifying enzymes. This is further evidenced by Sun et al.,
who demonstrated in bronchial epithelial cells that chromium
increased expression of the H3K9-specific methyltransferase G9a,
which was correlated with increases of di and tri-methylated
H3K9 as well as H3K4 (Sun et al., 2009). H3K9me occurred not
only globally, but also at the promoter of MLH1, a DNA mis-
match repair enzyme. Chromium exposure decreased expression
of MLH1 (Sun et al., 2009), suggesting that chromium silences
expression of this gene through H3K9me, providing an epige-
netic link between chromium and carcinogenesis. Repression
of E-cadherin is a possible mechanism of chromium-mediated
oncogenic transformation of lung epithelial cells, and chromium
increased binding of HDAC1 to the E-cadherin promoter, sug-
gesting increased histone acetylation as a repressive mecha-
nism, though H3K9Ac status was not confirmed (Ding et al.,
2013).
Chromium associated changes in miRNA expression
Peripheral blood leukocytes from workers at an electric furnace
steel plant were analyzed for metals and miRNA levels; chromium
was negatively associated with miR-146a (Bollati et al., 2010). He
et al. showed that miR-143 is repressed in chromium-transformed
human lung epithelial cells, and this repression activates angio-
genesis through an IL-8-insuling growth factor receptor (IGFR)-
HIF-1 pathway (He et al., 2013).
Epigenetic data in the chromium risk assessment process
As an example of the utilization of chromium associated epige-
netic modification data to inform the risk assessment process,
chromium has been associated with histone modifications in
a dose-dependent manner. After exposure to chromate, A549
cells showed increased H3K9me2 and decreased H3K4me3 in
the promoter region of the mismatch repair gene MLH1 (Sun
et al., 2009). Furthermore, the results demonstrated that histone
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alterations were correlated with decreased expression of MLH1.
MLH1 has been shown to be associated with multiple cancer
and non-cancer endpoints including hereditary colorectal cancer
(Kuismanen et al., 2000; Pokorny et al., 1997). As a result, dose-
dependent histone modification data may be useful in the hazard
identification and dose-response assessment, and may help to
identify the molecular mechanisms linking metals exposure to
carcinogenesis or other disease outcomes.
DISCUSSION
INTEGRATION OF EPIGENETIC DATA INTO THE RISK ASSESSMENT
PROCESS
The risk assessment process attempts to define associations
between specific health outcomes and exposure to a specific agent,
and to determine levels of exposure at which negative health out-
comes associated with the exposure are minimized. The process
is systematic and driven by available data in order to understand
the mechanistic links between a range of exposures and adverse
health effects.
In the present review, a discussion of the potential use of epige-
nomic data in the risk assessment process is built upon strategies
aimed at inclusion of genomic data in the risk assessment pro-
cess (EPA, 2002). Epigenomic data has the potential to inform
both mechanisms and modes of action and in combination with
genomic data may identify novel modes of action. Epigenomic
data may also be used to identify toxicodynamic (TD) and toxi-
cokinetic (TK) data, inter- and intraspecies differences in TD and
TK, exposure assessments, and dose-response assessments.
In the context of the risk assessment process (Figure 2),
the first step, hazard identification, seeks to establish whether
toxic-metal exposure is associated with a disease or mechanism
of action leading to disease. Traditionally, toxicological studies
have investigated exposure to toxic-metals and health outcomes,
but due to the window of time between exposure and disease
detection, epigenetic alterations may serve as better biomarkers
linking historic metal exposure with disease. In the event that
these epigenetic modification result in functional changes in gene
expression and subsequent health outcomes, the epigenetic mod-
ification may serve to uncover a basis for metal-induced diseases
where traditional toxicological studies have been limited.
Next, epigenetic alterations associated with toxic metals expo-
sure may be used in the dose-response analysis, which seeks to
determine if exposure is associated with health outcomes in a
dose-dependent manner. If a dose-response relationship is iden-
tified between exposure, an epigenetic alteration, and functional
gene expression leading to the disease, such epigenetic alterations
may be able to inform the dose-response analysis.
The third step of the risk assessment process, exposure analy-
sis, seeks to determine the route, degree, frequency, and duration
of exposure for a particular agent. While studies have yet to sub-
stantiate toxic-metal induced epigenetic alterations as biomarkers
of exposure, cord blood gene-specific expression data has been
shown to be highly predictive of in utero arsenic exposure (Fry
et al., 2007). If epigenetic alterations predict toxic metals expo-
sure, such epigenetic data could be useful in informing the
exposure components in the risk assessment process, and as an
example, may supplement current arsenic biomarkers such as
urine, blood, hair, or toenail samples (NRC, 1999).
Understanding the mechanism of action and mode of action
of a particular agent in the disease process is a key component
FIGURE 2 | Incorporating epigenetic data into the risk assessment
process. Epigenetic data may be used to inform each component of the risk
assessment process. The risk assessment process consists of four key steps
(A, left box); hazard identification, dose-response assessment, exposure
assessment, and risk characterization. The intent of each step is met by
applying clinical and epidemiological data to the criteria of each step (A, right
box). Epigenetic data can be used to inform the risk assessment process by the
integrationof keydata into thecriteria framework (B)of eachstep in theprocess.
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Table 1 | Epigenetic alterations induced by inorganic arsenic (iAs) or iAs metabolites.
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA methylation A549 (human lung
carcinoma cells)
Global and
targeted/hypermethlation
TP53 0–10μM
NaAsO2,
0–300μM
KH2AsO4,
0–2000μM
DMA
Mass and Wang, 1997
DNA methylation Caco-2 (human colon
cancer cells)
Global and
targeted/hypermethylation
TP53 0, 1, or 2μmol/L
As3+ for 7 d
Davis et al., 2000
DNA methylation UOK (human kidney cell
line)
A549 (human lung
carcinoma)
Targeted/hypermethylation – 0.08–2μM
NaAsO2 or
30–300μM
NaH2AsO4
Zhong and Mass, 2001
DNA methylation RWPE-1 (immortalized
human prostate epithelial
cells)
Global/hypomethylation – 5μM NaAsO2 Benbrahim-Tallaa et al.,
2005
DNA methylation Peripheral blood
leukocytes (West Bengal,
India, n = 158)
Targeted/hypermethylation TP53
TP16
<50 to >500μg
iAs in DW for
>6mo
Chanda et al., 2006
DNA methylation HepG2 (human liver
cancer cell line)
Targeted/hypermethylation ↓ TP16*
↓ CDH1*
↓ RASSF1A*
↓ GSTP1*
2–10μM of
As2O3
Cui et al., 2006b
DNA methylation Bladder tumors (New
Hampshire, USA,
n = 351)
Targeted/hypermethylation RASSF1A
PRSS3
95% percentile:
=0.26μg/g As
Marsit et al., 2006a
DNA methylation SV-HUC-1 (normal human
urothelial cell line)
Targeted/hypermethylation ↓ DAPK* 2, 4, and 10μM
NaAsO2
Chai et al., 2007
DNA methylation Uroepithelial carcinoma
tumor specimens
(Taiwan, n = 38)
Targeted/hypermethylation DAPK Chen et al., 2007
DNA methylation Peripheral blood
leukocytes (Dhaka,
Bangladesh, n = 294)
Global/hypermethylation – 0.1–860μg/L As Pilsner et al., 2007
DNA methylation HaCat (immortalized
human keratinocytes)
Global/hypomethylation – 0.2μM As3+ Reichard et al., 2007
DNA methylation Peripheral blood
leukocytes (Guizhou,
China, n = 170)
Targeted/hypermethylation ↓ TP16* Zhang et al., 2007
DNA methylation RWPE-1 (immortalized
human prostate epithelial
cells)
Targeted/hypomethylation – 5μM As3+ for
up to 16wk
Coppin et al., 2008
DNA methylation UROtsa (immortalized
human urothelial cells)
Global/differentially methylated – 1μM As (III) or
50 nM MMA (III)
Jensen et al., 2009a
DNA methylation Peripheral blood
leukocytes (Dhaka,
Bangladesh, n = 386)
Global/hypermethylation – 26–208μg/L As Pilsner et al., 2009b
(Continued)
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Table 1 | Continued
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA methylation Molt4, MUTZ-1, U937,
U266 and CA46
(malignant hematological
cell lines)
Targeted/hypomethylation ↑ CDKN2B*
↑ CDKN2A*
0.5, 1.0, or
2.0μM As2O3
Fu et al., 2010
DNA methylation Peripheral blood
leukocytes (West Bengal,
India, n = 64)
Global/hypermethylation – <50 to >500μg
iAs in DW for
>6mo
Majumdar et al., 2010
DNA methylation SV-HUC-1 (normal human
urothelial cell line)
Targeted/hypermethylation ↑ RECK* 1, 4, or 10μM
NaAsO2
Huang et al., 2011
DNA methylation Peripheral blood
leukocytes (Zimapan,
Mexico, n = 16)
Genome-wide/hypermethylation 181 DMGs 7–77μg/g
Creatinine
Smeester et al., 2011
DNA methylation Peripheral blood
leukocytes (Matlab,
Bangladesh, n = 101)
Global/male: hyper
female: hypo
– 127.6μg/L mean
urinary arsenic
Pilsner et al., 2012
DNA methylation Peripheral blood
leukocytes (Zimapan,
Mexico, n = 16)
Genome-wide/hypomethylation 812 DMGs 3.6–31.8 ng
As/ml tAs in
urine
Bailey et al., 2013
DNA methylation Peripheral blood
leukocytes (New
Hampshire, USA,
n = 134)
Genome-wide/hypermethylation 68,353 DM CpG
loci
0.03–100μg/L
DW As
Koestler et al., 2013
DNA methylation Peripheral blood
mononuclear cells
(Bangladesh, n = 320)
Global/hypermethylation – 0–300+ μM/L
DW As
Niedzwiecki et al.,
2013
DNA methylation Peripheral blood
leukocytes (Bangladesh,
n = 44)
Genome-wide/hypermethylation 71 DMGs Median =
12μM/L in DW
Kile et al., 2014
DNA methylation HepG2 and HEK-293
(human liver cancer cell
line and human
embryonic cell line)
(Murshidabad, West
Bengal, India, n = 245)
Targeted/hypomethylation ↑ ERCC2* 0–10μM As(III) Paul et al., 2014
DNA methylation Human urothelial
carcinoma tumors
(Southwestern Taiwan,
n = 28)
Genome-wide/hypermethylation
(majority)
213 DMGs 0.25–20.08 ppm
yr As
Yang et al., 2014
miRNA TK-6 (immortalized
human lymphoblast cell
line)
Genome-wide/
↓ miR-210
↑ miR-22
↑ miR-34a
↑ miR-221
↑ miR-222
– 2μM NaAsO2
for 6 d
Marsit et al., 2006b
miRNA T24 (human bladder
carcinoma)
Targeted/
↓ miR-19a
↑ miR-222
↓ PTEN* 4μM As2O3 Cao et al., 2011
(Continued)
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Table 1 | Continued
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
miRNA Hep-G2 (human
hepatocellular carcinoma)
Genome-wide/
↑ miR-24
↑ miR29a
↑ miR30a
↑ miR-210
– 4μM As2O3 Meng et al., 2011
miRNA Newborn cord blood
(Gómez Palacio, Mexico,
n = 40)
Genome-wide/
↑ let-7a
↑ miR-107
↑ miR-126
↑ miR-16
↑ miR-17*
↑ miR-195
↑ miR-20a
↑ miR-20b
↑ miR-26b
↑ miR-454
↑ miR-96
↑ miR-98
– 6.2–319.7μg/L
U-tAs
Rager et al., 2014
Histone modification WI-38 (human diploid
fibroblast)
↑ H3S10p ↑ C-Jun*
↑ C-Fos*
400μM As3+ for
10, 30, 60min
Li et al., 2003
Histone modification CGL-2 (hybrid of the HeLa
adenocarcinoma cell line
and normal human
fibroblasts)
↑ H2AXp – 0–10μM As3+
for 24 h
Yih et al., 2005
Histone modification RPMI7951 (human
malignant melanoma
epithelial-like cell line)
↑ H2AXp – 2.5μM As3+ for
24 h
Zykova et al., 2006
Histone modification UROtsa (human
urothelium
non-tumorigenic cell line)
↑ H3ac
↑ H3K27me3
↑ H3K4me2
↑ H3K9me2
↑ DBC1*
↓ FAM83A*
↓ ZSCAN12*
↓ C1QTNF6*
↑ NEFL*
–
1μM As3+
(chronic)
Jensen et al., 2008
Histone modification Hep-G2 (human
hepatocarcinoma line)
↑ H3K9ac – 7.5, 10, 15, and
50μM
NaAsO2for 2, 4,
12, or 24 h
Ramirez et al., 2008
Histone modification UROtsa (human bladder
epithelial cells)
↓ H4K16ac – 1, 3, 10μM
NaAsO2or
MMAIIIO at 0.3,
1, 3μM
Jo et al., 2009
Histone modification Human lung carcinoma
cells (A549)
↑ H3K4me3 - 1μM As3+ for
24 h
Zhou et al., 2009
Histone modification Peripheral blood
Leukocytes (Brescia, Italy
n = 63)
↑ H3K4me2
↑ H3K9ac
– 0.01–0.31μg/m3
arsenic PM for
3 d
Cantone et al., 2011
(Continued)
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Table 1 | Continued
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
Histone modification Urine (Bangladesh,
n = 40)
↑ H3K9me2
↓ H3K9Ac
H3K4me3
H3K27me3
H3K27Ac
H3K18Ac
– 91.5μg/L
urinary arsenic
Chervona et al., 2012
Histone modification HaCaT (human
keratinocytes)
↑ H4R3me2
↑ H3R17me2
↑ PRMT1*
↑ PRMT4*
10μM NaAsO2
for 2, 4, 8, 12,
24 h
Huang et al., 2013
Histone modification UROtsa (human bladder
epithelial cells)
↓ H3K9me2
↓ H3K27me3
↑ H3Ac
↑ WNT5A* 1μM As3+
(chronic)
Jensen et al., 2009b
↑, increased; ↓, decreased; *, functionally validated at the expression level; –, not functionally validated at the expression level; Global refers to global methylation
patterns; Genome-wide refers to high throughput gene-specific assays; DMGs, differentially methylated genes.
Table 2 | Epigenetic alterations induced by mercury.
Epigenetic
modification
Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA
methylation
Blood (San Francisco,
USA, n = 58)
Targeted/hypermethylation GSTM1 Blood Hg:
2.9μg/L
Hanna et al., 2012
DNA
methylation
Buccal mucosa samples
(Michigan, USA, n = 131)
Targeted/hypomethylation SEPP1 Hair Hg:
0.31–0.44 (μg/g)
Urine Hg:
0.60–0.83 (μg/L)
Goodrich et al., 2013
mi-RNA NT2 (carcinoma
pluripotent stem cells)
Genome-wide/
↑ miR-302b
↑ miR-367
↑ miR-372
↑ miR-196b
↑ miR-141
– 400 nM MeHgCl
for 2–36 d
Pallocca et al., 2013
↑, increased; ↓, decreased; *, functionally validated at the expression level; –, not functionally validated at the expression level; Global refers to global methylation
patterns; Genome-wide refers to high throughput gene-specific assays; DMGs, differentially methylated genes.
for the risk assessment process, and the use of epigenomic data
may help to fill in current knowledge gaps. Associations between
epigenetic alterations, gene expression, and disease initiation or
progression may inform research into the modes of action of var-
ious toxic-metals. Additionally, epigenomic data has the potential
to uncover whether toxic-metals may produce heritable epige-
netic alterations. Ultimately such epigenomic data may directly
play a role in the risk characterization step, and add additional
accuracy to the risk assessment process.
EPIGENETIC ALTERATIONS AS BIOMARKERS OF METALS EFFECTS
There is the potential that epigenetic alterations can be used
as biomarkers of adverse health outcomes, representing a new
tool in predicting metal-associated diseases (Mulero-Navarro and
Esteller, 2008; Bock, 2009). Stable epigenetic marks that are
associated with a particular agent and adverse health outcome
may also inform inter-individual differences in TK and TD.
Additionally, as patterning of epigenetic marks naturally differ
with the age of an individual (Calvanese et al., 2009), these
data may be employed to estimate if exposure occurred during
sensitive windows of development (pre- or post-fertilization, in
utero, or puberty), which are associated with varying health out-
comes. Such biomarkers associated with disease may be used
as an additional tool that could inform the risk assessment
process.
In the clinical settings, epigenetic biomarkers may be use-
ful as early detection of changes associated with chronic dis-
eases or cancers. For example, epigenetic alterations associated
with tumor suppressors or oncogenes may inform an individ-
ual’s cancer susceptibility (Verma et al., 2003). Specific epige-
netic marks on such genes can be associated with the stage of
cancer development, thus informing diagnosis and treatment.
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Table 3 | Epigenetic alterations induced by lead.
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA methylation Maternal Tibia (Mexico,
n = 103)
Global/hypomethylation – 10.5 ± 8.4 (μg/g) Pilsner et al., 2009a
DNA methylation Peripheral blood
leukocytes (Greece,
n = 19)
Targeted/hypermethylation TP16 6–100 (ug/dL) Kovatsi et al., 2010
DNA methylation Patella (USA, n = 2280) Global/hypomethylation – 27.4 ± 19.7 (g/g) Wright et al., 2010
DNA methylation Peripheral blood
leukocytes (San
Francisco, California,
n = 41)
Targeted/hypomethylation COL1A2 0.3–8.8 (μg/L) Hanna et al., 2012
DNA methylation A431 (epidermoid
carcinoma cells)
Targeted/hypomethylation ↑ COX-2* 0.1–10μM for
0.5–2 h
Tsai et al., 2014
mi-RNA Peripheral blood
leukocytes
(Brescia, Italy, n = 63)
Targeted/
↑ miR-222
↓ miR-146a
- 3 d lead PM Bollati et al., 2010
↑, increased; ↓, decreased; *, functionally validated at the expression level; –, not functionally validated at the expression level; Global refers to global methylation
patterns; Genome-wide refers to high throughput gene-specific assays; DMGs, differentially methylated genes.
These techniques have the possibility of being applied to metal-
induced carcinogenesis.
Clearly, additional studies are needed to ascertain metal-
associated epigenetic alterations not only at different exposure
levels, but also at varied developmental time points. Such infor-
mation is critical not only to refine dose-response predictions,
but to differentiate between epigenetic alterations that naturally
differ with respect to age (Bocklandt et al., 2011), and those asso-
ciated with toxic-metal exposure. Additionally, the focus on these
changes would need to be shown to be exposure specific and inde-
pendent of other confounding agents. Such research would need
to also assess whether such epigenetic marks were loci and tissue
specific, and whether such biomarkers were representative across
populations.
EPIGENETIC ALTERATIONS AS PREDICTORS OF METAL-INDUCED GENE
EXPRESSION
Epigenetic alternations may be a useful tool in predicting dif-
ferential gene expression in response to toxic-metal exposure.
As mentioned previously, epigenetic alterations can affect gene
expression in a number of ways, including histone modifications
which influence transcription, expression of miRNAs which regu-
late mRNA stability and subsequent translation, andmodification
of CpG methylation patterns leading to altered transcription. Of
the three, alteration of DNA methylation patterns is supported
by the largest body of evidence. Methylation of CpG sites in the
promoter regions of genes is often associated with silencing the
expression of that gene (Weber et al., 2007). While many stud-
ies have shown a global inverse association between methylation
and expression, it is worth noting that such an association is not
universal (Bell et al., 2011), and as such epigenetic data should be
complemented with corresponding gene expression data. There is
the potential that some epigenetic marks may enable researchers
to predict gene specific expression changes and their associated
health outcomes.
EPIGENETIC ALTERATIONS AS PREDICTORS OF TOXICITY AND
DISEASE
The potential for heritability associated with forms of epige-
netic alterations provides novel possibilities in the risk assessment
process. Epigenetic modifications can be mitotically inherited,
and as a result may be passed on to future generations (Rakyan
and Whitelaw, 2003). As a result, heritable epigenetic alterations
may play a pivotal role in determining inter-individual variation
in susceptibility to disease based on the differences in indi-
vidual’s ancestral environmental exposures. Because epigenetic
reprogramming is utilized by the body as a mechanism to ensure
proper cell development and function (Reik et al., 2001), dis-
ruption of these patterns during key developmental windows
can produce stable phenotypic and functional changes in an
individual (Tang and Ho, 2007).
As discussed in the review, in utero exposure to several toxic
metals such as arsenic and cadmium are associated with epi-
genetic alterations. Epigenetic alterations not only provide the
possibility of informing later life health outcomes, but may be
useful in predicting adverse health outcomes from a specific early
life metal exposure. Inter-individual differences in metabolism
may actually be mediated in part by the epigenetic modifications.
In certain cases, metal-specific epigenetic alterations may have the
possibility of informing researchers of an individual’s previous
exposure and their specific associated changes in gene expression
or health effects.
In addition, epigenetic alterations to the germ line may
provide insight into trans-generational differences in disease
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Table 4 | Epigenetic alterations induced by cadmium.
Epigenetic
modification
Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA methylation RWPE-1 (human
prostate epithelial cells)
Global and
targeted/hypermethylation
↓ TP16*
↓ RASSF1A*
10μM CdCl2 for
10wk
Benbrahim-Tallaa et al., 2007
DNA methylation K562 (chronic
myelogenous leukemia
cells)
Global/hypomethylation – 2.0μM for
24/48 h
Huang et al., 2008
DNA methylation HLF (human embryo
lung fibroblast cells)
Global/hypermethylation – 0–1.5μM for
2mo
Jiang et al., 2008
DNA methylation JEG-3 (human
choriocarcinoma cells)
Targeted/hypomethylation ↑ HSD11B2* 0.5, 1μM Cd2+
for 24 h
Ronco et al., 2010
DNA methylation RWPE-1 (human
prostate epithelial cells)
Global/differential
methylation
– 10μM Cd2 for
1 yr
Severson et al., 2012
DNA methylation UROtsa (human
urothelial cells)
Global/differential
methylation
– 1μM Cd2 for
1 yr
Severson et al., 2012
DNA methylation 16HBE (human
bronchial epithelial
cells)
Global and
Targeted/hypermethylation
↓ hMSH2*
↓ ERCC1*
↓ XRCC1*
↓ hOGG1*
5–15μM CdCl2
for 3–4mos
Zhou et al., 2012
DNA methylation Maternal venous blood
and newborn cord
blood (Durham, NC,
n = 34)
Genome-wide/hyper and
hypo methylation
– 0–1.05μg/L Cd
(maternal)
Sanders et al., 2014
miRNA Peripheral blood
leukocytes (Italy,
n = 63)
Genome-wide/miR-146a – 0.01μg/m3 3 d Bollati et al., 2010
miRNA HepG2 (human
hepatoblastoma cells)
Genome-wide/
↓ let-7 family
↓ miR-1233
↓ miR-1275
↓ miR-130a
↓ miR-15b
↓ miR-15b*
↓ miR-23b
↓ miR-361-5p
↓ miR-455-3p
– 2, 10μM CdCl2
for 24 h
Fabbri et al., 2012
miRNA Human bronchial
epithelial cells
Targeted/
↑ miR-101
↑ miR-144
↓ CFTR* 2μM CdCl2
24 h
Hassan et al., 2012
Histone modification MCF-7 (human breast
adenocarcinoma cells)
↓ H3ac – 5μg/mL
CdTeQD for 4,
24 h
Choi et al., 2008b
Histone modification UROtsa (human
urothelial cells)
↑ H3K4me3
↑ H3K9me3
↑ H3K27me3
MT3 1μM CdCl2
∼60d
Somji et al., 2011
Histone modification In vitro kinase assay ↓ H3p – 1–25μM CdCl2 Barcia-Sanjurjo et al., 2013
↑, increased; ↓, decreased; *, functionally validated at the expression level; –, not functionally validated at the expression level; Global refers to global methylation
patterns; Genome-wide refers to high throughput gene-specific assays; DMGs, differentially methylated genes.
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Table 5 | Epigenetic alterations induced by chromium.
Class Cell lines or biological
samples (location)
Assessment/modification Identified gene
targets
Dose (range) References
DNA methylation Lung cancer tumors
(Tokushima, Japan,
n = 68)
Targeted/hypermethylation ↓TP16* 12–38 yr
Chromate
Kondo et al., 2006
DNA methylation Lung cancer tumors
(Tokushima, Japan,
n = 61)
Targeted/hypermethylation APC
MGMT
↓ hMLH1*
↓ TP16*
12–38 yr
chromate
Ali et al., 2011
DNA methylation Red blood cells
(Shandong, China,
n = 175)
Global/hypomethylation – 0.96–115.01
(μg/L)
Wang et al., 2012
DNA methylation A549 (human B
lymphoblastoid cell line
and lung cell line)
Global and
targeted/hypomethylation
↑ TP16* 5–15μM
K2Cr2O7, 1.25–5
(μg/cm2)
PbCrO4
Lou et al., 2013
Histone modification CNTRL (human skin
fibroblasts)
↑ H2AXp – 6μM Cr(VI) Vilcheck et al., 2006
Histone modification A549 (human lung
carcinoma)
↑ H3K4me (2,3)
↑ H3K9me (2,3)
↓ MLH1* 5–10μM Cr(VI) Sun et al., 2009
Histone modification A549 (human lung
carcinoma)
↑ H3K4me (2,3) – 0.5–10μM Cr(VI) Zhou et al., 2009
miRNA Blood leukocytes
(Brescia, Italy, n = 63)
Targeted/
↑ miR-222
– 3 d PM
chromium
Bollati et al., 2010
miRNA BEAS-2B (human lung
epithelial cells)
Targeted/
↓ miR-143
– 6 mo exposure
to 1μM Cr(VI)
He et al., 2013
↑, increased; ↓, decreased; *, functionally validated at the expression level; –, not functionally validated at the expression level; Global refers to global methylation
patterns; Genome-wide refers to high throughput gene-specific assays; DMGs, differentially methylated genes.
patterns or susceptibility (Sasaki and Matsui, 2008; Skinner,
2008). Individuals in the F3 generation, with no direct contact to
the originally exposed F0 ancestor may still experience functional
changes as a result of their ancestor’s historical environment.
While such a concept has yet to be shown in humans exposed
to toxic-metals, researchers have shown exposure to famine is
associated with sex-specific mortality differences in an individ-
ual’s grandchildren (Heijmans et al., 2008). Additionally, research
in rodent models has shown differences in physiology and can-
cer susceptibility persist after four generations in rats originally
exposed to various endocrine disruptors (Anway et al., 2005).
While the transgenerational nature of epigenetic alterations is
under debate, it is worth noting such a phenomenon could
greatly inform the risk assessment process if heritable epigenetic
alterations associated with disease can inform intra-individual
differences in disease susceptibility.
FINAL CONSIDERATIONS
While the number of publications on metals-induced epigenetic
changes continues to rise, there are gaps in research that need
to be filled prior to their incorporation into the risk assessment
process. Where data are derived from humans, sample sizes need
to be large and data confirmed and replicated cross-cohorts. The
data should be collected at different time points during develop-
ment and/or growth to determine the temporal stability of the
changes and establish potential developmental windows of sus-
ceptibility. Moreover, additional studies are required to examine
the associations between epigenetic alterations, functional cellu-
lar consequences and adverse health outcomes through the use
of epidemiologic as well as traditional toxicological studies. Such
studies require an examination across multiple tissues, at multiple
doses, for multiple durations, and at different time periods during
development or life stage.
The epigenome serves as a link between an individual’s
genome and their response to environmental cues. As such, the
changes to the epigenome can act as both a snapshot of an indi-
vidual’s response to various environmental stressors, as well as
a putative predictor of an individual’s susceptibility to future
stressors and disease outcome. In order to fully understand these
relationships it will be necessary to conduct studies that com-
pare both epigenetic data with functional measures such as gene
and protein expression within the same study and controlled
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exposure scenarios. Taken together, the epigenetic data may pro-
vide novel contributions to the risk assessment process, but
currently much remains unknown about the association between
these modifications and functional changes in gene and protein
expression.
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